Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Target Price
The average target price of LSTA is 9.7 and suggests 92% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell